Streetbeat News

Products Services

VNDA

Vanda Pharmaceuticals announced an FDA update regarding the supplemental New Drug Application (NDA) for HETLIOZ in the treatment of insomnia. This development is crucial for the company as it seeks to expand the indications for HETLIOZ, potentially broadening its market and therapeutic reach.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:03 pm

CMND

Clearmind Medicine Inc. has received divisional patent approval in China for its psychedelic-based treatment targeting binge behaviors. This approval strengthens the company's intellectual property portfolio, which includes 15 utility patent families and a total of 51 patents and pending applications globally. The company's MEAI molecule has shown promise in pre-clinical studies for regulating binge behaviors and addiction, particularly in relation to Alcohol Use Disorder and binge drinking.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:52 pm

SMFL

Smart for Life, Inc. (SMFL), a global leader in Health & Wellness, has partnered with SGS Nutrasource to assist in regulatory, product development, and testing solutions. This collaboration aims to support Smart for Life's strategic expansion and acceleration of M&A activities.

Portfolio Pulse from Charles Gross

February 05, 2024 | 12:43 pm

BRTX

BioRestorative Therapies presented preliminary 26 and 52 week blinded data from the ongoing Phase 2 trial of BRTX-100 at the Orthopaedic Research Society 2024 Annual Meeting. The trial focuses on subjects with chronic lumbar disc disease.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:38 pm

BBIO

The FDA has accepted BridgeBio Pharma's New Drug Application for Acoramidis for the treatment of Transthyretin Amyloid Cardiomyopathy, with a decision expected by November 29.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:34 pm

MBOT

Microbot Medical has submitted an Investigational Device Exemption (IDE) application to the FDA, aiming to gain approval to start its pivotal clinical trial in the US. This step is crucial for advancing the company's medical device through the regulatory process and potentially bringing it closer to market.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:33 pm

BA

Boeing shares are trading lower due to the discovery of new quality defects in its 737 MAX airplanes.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:28 pm

META

Meta's Oversight Board has criticized the company's current deepfake rules as 'incoherent' after reviewing a controversial video of President Joe Biden. The board suggests extending the manipulated media policy to cover all audio and video content, not just AI-generated material. Meta plans to update its policy to adapt to the evolving AI landscape. This comes amid growing concerns over deepfake content and its potential misuse, with Meta committed to advancing AI technology.

Portfolio Pulse from Benzinga Neuro

February 05, 2024 | 12:21 pm

ELBM

Electra Battery Materials has announced successful optimizations in its battery materials recycling trial at its Ontario refinery complex, leading to improved recoveries of lithium, nickel, cobalt, and other critical minerals. The plant-scale black mass recycling trial is largely complete, with an internal report on proprietary methodologies, optimizations, and growth scenarios underway.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:09 pm

BRKR

At the SLAS2024 International Conference and Exhibition, Bruker Corporation introduced the 'Triceratops' SPR #64, a new Surface Plasmon Resonance (SPR) instrument designed to enhance drug discovery through improved SPR throughput, sensitivity, and data quality. SPR technology is crucial for the real-time, label-free analysis of molecular interactions in drug discovery.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:06 pm